Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors

Annals of Oncology

Volumn 26, Issue 5, 2015, Pages 838-847

  Serpico, D ^a   Trama, A ^b   Haspinger, E R ^a   Agustoni, F ^a   Botta, L ^b   Berardi, R ^c   Palmieri, G ^d   Zucali, P ^e   Gallucci, R ^a   Broggini, M ^f   Gatta, G ^b   Pastorino, U ^b   Pelosi, G ^b   De braud, F ^b   Garassino, Marina C ^a  

^a Department of Oncology and Hematology   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

Biological agents; Chemotherapy; Targeted therapy; Thymic carcinoma; Thymic epithelial tumors; Thymoma

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CIXUTUMUMAB; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FIGITUMUMAB; GEFITINIB; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; METHYLPREDNISOLONE; OCTREOTIDE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR; STEM CELL FACTOR RECEPTOR; UNINDEXED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; TUMOR MARKER;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THYMIC EPITHELIAL TUMOR; THYMOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR PROMOTION; ADVERSE EFFECTS; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; PATHOLOGY; SIGNAL TRANSDUCTION; THYMUS NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; BIOMARKERS, TUMOR; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; SIGNAL TRANSDUCTION; THYMUS NEOPLASMS; TREATMENT OUTCOME;

EID: 84929077760     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu527     Document Type: Review

References (86)

1. Siesling S, van der Zwan JM, Izarzugaza I et al. Rare thoracic cancers, including peritoneum mesotelioma. Eur J Cancer 2012; 48: 949-960.
2. Gatta G, van der Zwan JM, Casali PG et al. Rare cancers are not so rare: the burden of rare cancers in Europe. Eur J Cancer 2011; 47: 2493-2511.
3. Engels EA. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010; 5(10 Suppl 4): S260-S265.
4. Mariano C, Ionescu DN, Cheung WY et al. Thymoma. A population-based study of the management and outcomes for the province of British Columbia. J Thorac Oncol 2013; 8: 109-117.
5. de Jong WK, Blaauwgeers JLG, Schaapveld M et al. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 2008; 44(1): 123-130.
6. Masaoka A, Monden Y, Nakahara K et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981; 48: 2485-2492.
7. Rosai J. Histological typing of tumors of the thymus. In: WHO International Histological Classification of Tumors. New York: Springer-Verlag, 1999; 5-15.
8. Kim ES, Putnam JB, Komaki R et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004; 44(3): 369-379.
9. Bonomi PD, Finkelstein D, Aisner S et al. EST 2582 phase II trial of cisplatin in metastatic or recurrent thymoma. Am J Clin Oncol 1993; 16: 342-354.
10. Highley MS, Parnis FX, Karapetis C et al. Treatment of invasive thymoma with single-agent ifosfamide. J Clin Oncol 1999; 17: 2737-2744.
11. Loehrer PJ Sr, Yiannoutsos CT, Dropcho S et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2006; 24: 383s (suppl): abstr 7079.
12. Fornasiero A, Daniele O, Ghiotto C et al. Chemotherapy for invasive thymoma: a 13-year experience. Cancer 1991; 68: 30-33.
13. Rea F, Sartori F, Loy M et al. Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 1993; 106(3): 543-549.
14. Koizumi T, Takabayashi Y, Yamagishi S et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). Am J Clin Oncol 2002; 25: 266-268.
15. Berruti A, Borasio P, Gerbino P et al. Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 1999; 81(5): 841-845.
16. Loehrer PJ Sr, Kim K, Aisner SC et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial-the Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 1994; 12: 1164-1168.
17. Loehrer PJ Sr, Chen M, Kim K et al. Chemotherapy of invasive thymoma. J Clin Oncol 1997; 15: 3093-3099.
18. Shin DM, Walsh Garrett L, Komaki R et al. A multidisciplinary approach to therapy for unresectablemalignant thymoma. Ann Intern Med 1998; 129: 100-104.
19. Yokoi K, Matsuguma H, Nakahara MD et al. Multimodality treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007; 2: 73-78.
20. Macchiarini P, Chella A, Ducci F et al. Neoadjuvant chemotherapy, surgery, and postoperative radiation therapy for invasive thymoma. Cancer 1991; 68(4): 706-713.
21. Lucchi M, Ambrogi MC, Duranti L et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005; 79(6): 1840-1844.
22. Giaccone G, Ardizzoni A, Kirkpatrick A et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1996; 14: 814-820.
23. Mineo T, Mineo D, Onorati I et al. New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma: a retrospective analysis. Ann Surg Oncol 2010; 17: 3022-3029.
24. Loehrer PJ Sr, Jiroutek M, Aisner S et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 2001; 91: 2010-2015.
25. Grassin F, Paleiron N, André M et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: a French experience. J Thorac Oncol 2010; 5(6): 893-897.
26. Igawa S, Murakami H, Takahashi T et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 2010; 67(2): 194-197.
27. Furugen M, Sekine I, Tsuta K et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol 2011; 41(8): 1013-1016.
28. Lemma GL, Loehrer PJ Sr, Lee JW et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99. J Clin Oncol 2008; 26: 428s (suppl): abstr 8018.
29. Takeda K, Hirai F, Yamanaka T et al. A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. J Clin Oncol 2013; 31 (suppl): abstr 7529.
30. Okuma Y, Hosomi Y, Takagi Y et al. Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 2011; 74: 492-496.
31. Okuma Y, Hosomi Y, Watanabe K et al. Key components of chemotherapy for thymoma and thymic carcinoma: anthracycline-, carboplatin-, or cisplatin-based chemotherapy. J Clin Oncol 2014; 32 (suppl): abstr e18556.
32. Palmieri G, Merola G, Federico P et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). Ann Oncol 2010; 21: 1168-1172.
33. Buonerba C, Ottaviano M, Federico P et al. Capecitabine plus gemcitabine in thymic epithelial tumors: final analysis of a phase II trial. J Clin Oncol 2014; 32: 5s (suppl): abstr 7528.
34. Strobel P, Hartmann M, Jakob A et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004; 350:2625-2626.
35. Li XF, Chen Q, Huang WX et al. Response to sorafenib in cisplatin resistant thymic carcinoma: a case report. Med Oncol 2009; 26: 157-160.
36. Chuah C, Lim TH, Lim AS et al. Dasatinib induces a response in malignant thymoma. J Clin Oncol 2006; 24: e56-e58.
37. Christodoulou C, Murray S, Dahabreh J et al. Response of malignant thymoma to erlotinib. Ann Oncol 2008; 19: 1361-1362.
38. Farina G, Garassino MC, Gambacorta M et al. Response of thymoma to cetuximab. Lancet Oncol 2007; 8: 449-450.
39. Yamaguchi H, Soda H, Kitazaki T et al. Thymic carcinoma with epidermal growth factor receptor gene mutations. Lung Cancer 2006; 52: 261-262.
40. Petrini I, Meltzer PS, Kim IK et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nat Genet 2014; 46(8): 844-849.
41. Petrini I, Meltzer PS, Zucali PA et al. Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors. Cell Death Dis 2012; 3(7): e351.
42. Shitara M, Okuda K, Suzuki A et al. Genetic profiling of thymic carcinoma using targeted next-generation sequencing. Lung Cancer 2014; 86(2): 174-179.
43. Kurup A, Burns M, Dropcho S et al. Phase II study of gefitinib treatment in advanced thymic malignancies. J Clin Oncol 2005; 23: abstr 7068.
44. Bedano PM, Perkins S, Burns M et al. A Phase II trial of erlotinib plus bevacizumab in patients with recurrent thymoma or thymic carcinoma. J Clin Oncol 2008; 15 (suppl): abstr 19087.
45. Giaccone G, Rajan A, Ruijter R et al. Imatinib mesylate in patients with WHO B3 thymomas and thymic carcinomas. J Thorac Oncol 2009; 4: 1270-1273.
46. Salter JT, Levis D, Yannoutsos C et al. Imatinib for the treatment of thymic carcinoma. J Clin Oncol 2008; 26 (suppl): abstr 8116.
47. Palmieri G, Marino M, Buonerba C et al. Imatinib mesylate in thymic epithelial malignancies. Cancer Chemother Pharmacol 2012; 69(2): 309-315.
48. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
49. Rajan A, Carter CA, Berman A et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours: a multicentre, open-label, phase 2 trial. Lancet Oncol 2014; 15(2): 191-200.
50. Isambert N, Freyer G, Zanetta S et al. A phase I dose escalation and pharmacokinetic (PK) study of intravenous aflibercept (VEGF trap) plus docetaxel (D) in patients (pts) with advanced solid tumors: preliminary results. J Clin Oncol 2008; 26: 177s (suppl): abstr 3599.
51. Thomas A, Rajan A, Berman AW et al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET). J Clin Oncol 2014; 32: 5s (suppl): abstr 7525.
52. Fiedler W, Giaccone G, Lasch P et al. Phase I trial of SU14813 in patients with advanced solid malignancies. Ann Oncol 2011; 22: 195-201.
53. Azad A, Herbertson RA, Pook D et al. Motesanib diphosphate (AMG 706), an oral angiogenesis inhibitor, demonstrates clinical efficacy in advanced thymoma. Acta Oncol 2009; 48(4): 619-621.
54. Palmieri G, Montella L, Martignetti A et al. Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer 2002; 94: 1414-1420.
55. Loehrer PJ Sr, Wang W, Johnson DH et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II trial. J Clin Oncol 2004; 22: 293-299.
56. Longo F, De Filippis L, Livi A et al. Efficacy and tolerability of long lasting octreotide in the treatment of thymic tumours: results of a pilot trial. Am J Clin Oncol 2012; 35: 105-109.
57. Steele NL, Plumb JA, Vidal L et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin Cancer Res 2008; 14: 804-810.
58. Giaccone G, Rajan A, Carter C et al. Phase II study of the histone deacetylase inhibitor belinostat in thymic malignancies. J Clin Oncol 2009; 27 (suppl): abstr 7589.
59. Besse B, Garassino MC, Rajan A et al. A phase II study of milciclib (PHA-848125AC) in patients (pts9 with thymic carcinoma (TC). J Clin Oncol 2014; 32:5s (suppl): abstr 7526.
60. Wakelee HA, Gubens MA, Burns M et al. A phase II study of saracatinib (AZD0530), a SRC inhibitor, administered orally daily to patients with advanced thymic malignancies. In: Presented at International Thymic Malignancy Group Conference. New York, NY. 5-6 May 2010.
61. Zucali PA, De Pas TM, Palmieri G et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy. J Clin Oncol 2014; 32:5s (suppl): abstr 7527.
62. Girard N, Shen R, Guo T et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009; 15: 6790-6799.
63. Pescarmona E, Pisacane A, Pignatelli E et al. Expression of epidermal and nerve growth factor receptors in human thymus and thymomas. Histopathology 1993; 23: 39-44.
64. Gilhus NE, Jones M, Turley H et al. Oncogene proteins and proliferation antigens in thymomas: increased expression of epidermal growth factor receptor and Ki67 antigen. J Clin Pathol 1995; 48: 447-455.
65. Henley JD, Koukoulis GK, Loehrer PJ, Sr. Epidermal growth factor receptor expression in invasive thymoma. J Cancer Res Clin Oncol 2002; 128: 167-170.
66. Suzuki E, Sasaki H, Kawano O et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006; 36: 351-356.
67. Meister M, Schirmacher P, Dienemann H et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 2007; 248: 186-191.
68. Yoh K, Nishiwaki Y, Ishii G et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008; 62: 316-320.
69. Aisner SC, Dahlberg S, Hameed MR et al. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol 2010; 5: 885-892.
70. Ionescu DN, Sasatomi E, Cieply K et al. Protein expression and gene amplification of epidermal growth factor receptor in thymomas. Cancer 2005; 103: 630-636.
71. Palmieri G, Marino M, Salvatore M et al. Cetuximab is an active treatment of metastatic and chemorefractory thymoma. Front Biosci 2007; 12: 757-761.
72. Girard N. Thymic tumors. Relevant molecular data in the clinic. J Thorac Oncol 2010; 5: S291-S295.
73. Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther 2012; 12(5): 685-695.
74. Girard N, Teruya-Feldstein J, Payabyab EC et al. Insulin-like growth factor-1 receptor expression in thymic malignancies. J Thorac Oncol 2010; 5: 1439-1446.
75. Zucali PA, Petrini I, Lorenzi E et al. Insulinlike growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas. Cancer 2010; 16: 4686-4695.
76. Cimpean AM, Raica M, Encica S et al. Immunohistochemical expression of vascular endothelial growth factor A (VEGF), and its receptors (VEGFR1, 2) in normal and pathologic conditions of the human thymus. Ann Anat 2008; 190: 238-245.
77. Tomita M, Matsuzaki Y, Edagawa M et al. Correlation between tumor angiogenesis and invasiveness in thymic epithelial tumors. J Thorac Cardiovasc Surg 2002; 124: 493-498.
78. Sasaki H, Yukiue H, Kobayashi Y et al. Elevated serum vascular endothelial growth factor and basic fibroblast growth factor levels in patients with thymic epithelial neoplasms. Surg Today 2001; 31: 1038-1040.
79. Bisagni G, Rossi G, Cavazza A et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma. J Thorac Oncol 2009; 4: 773-775.
80. Neuhaus T, Luyken J. Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma. Target Oncol 2012; 7(4): 247-251.
81. Ferone D, van Hagen PM, van Koetsveld PM et al. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999; 140: 373-380.
82. Kim DJ, Yang WI, Kim SH et al. Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg 2005; 28: 611-616.
83. Hirabayashi H, Fujii Y, Sakaguchi M et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. Int J Cancer 1997; 73: 639-644.
84. Hirose Y, Kondo K, Takizawa H et al. Aberrant methylation of tumour-related genes in thymic epithelial tumours. Lung Cancer 2009; 64: 155-159.
85. Tsuji T, Ikeda H, Tsuchikawa T et al. Malignant transformation of thymoma in recipient rats by heterotopic thymus transplantation from HTLV-I transgenic rats. Lab Invest 2005; 85: 851-861.
86. Mineo TC, Ambrogi V, Mineo D et al. Long term disease-free survival of patients with radically resected thymomas: relevance of cell-cycle protein expression. Cancer 2005; 104: 2063-2071.